ClinConnect ClinConnect Logo
Search / Trial NCT06768450

Online Meditation for Mild Cognitive Impairment and Mild Dementia

Launched by KING'S COLLEGE LONDON · Jan 6, 2025

Trial Information

Current as of October 26, 2025

Not yet recruiting

Keywords

Dementia Mild Cognitive Impairment Feasibility Acceptability Online Mindfulness Meditation

ClinConnect Summary

This clinical trial is studying an online mindfulness meditation program to see if it is easy for older adults with mild cognitive impairment (MCI) or mild dementia to use. The researchers want to find out how participating in this program might improve their mood, sleep, and overall quality of life. A total of 32 participants will be recruited and divided into small groups. They will join a weekly online meditation class for eight weeks and practice at home for about 20 minutes each day. Participants will also keep a simple record of their practice and feelings to help track their progress.

To be eligible for this study, participants should be 60 years or older and have MCI or mild dementia. They need to be able to use an electronic device like a smartphone or tablet and have internet access. It’s important that they can attend the sessions regularly and are willing to sign a consent form to participate. However, individuals with significant past experience in meditation, certain mental or physical health issues, or those who cannot communicate in English will not be eligible. This study aims to provide insights into how online meditation can benefit older adults facing these cognitive challenges.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 60 years or older.
  • MCI: Concern regarding a change in cognition, with impairment in one or more cognitive domains, including memory, executive function, attention, language, and visuospatial skills. Preservation of independence in functional abilities and does not meet the criteria for dementia, as described in the National Institute on Aging and Alzheimer's Association (NIA-AA) diagnostic guidelines.
  • Mild dementia: As described in the NIA-AA research framework, mild dementia is defined as substantial progressive cognitive impairment affecting several domains and/or neurobehavioral disturbances. Documented by the individual's report, an observer (e.g., a study partner) report, or by changes observed on longitudinal cognitive testing. Clearly evident functional impact on daily life, mainly affecting instrumental activities. No longer fully independent and requires occasional assistance with daily activities.
  • Access to an electronic device (e.g., smartphone, computer, or tablet) and the internet.
  • Ability and willingness to provide informed consent by signing the Consent Form.
  • Exclusion Criteria:
  • Current active or past significant experience with meditation.
  • Clinically significant mental or physical health disorder beyond MCI or dementia that may affect cognition and/or the ability to complete the study (e.g., severe depression, suicidality, psychosis, post-traumatic stress disorder (PTSD), major psychiatric diagnoses, social anxiety (e.g., difficulty participating in a group setting), or severe impairments in eyesight, hearing, or upper limb motor movements).
  • Inability to commit to attending classes (e.g., planning to miss three or more classes).
  • Lack of proficiency in English.
  • Diagnosed with moderate or severe dementia.

About King's College London

King's College London is a prominent research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the college leverages its extensive expertise in medicine, neuroscience, and public health to conduct rigorous studies aimed at improving patient outcomes. As a sponsor of clinical trials, King's College London prioritizes ethical standards, participant safety, and scientific integrity, fostering an environment that encourages groundbreaking research and the translation of findings into clinical practice. Through its state-of-the-art facilities and a diverse network of researchers, the institution strives to address critical health challenges and contribute to the global body of medical knowledge.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported